HC Wainwright Has Negative Forecast for STOK FY2029 Earnings

Stoke Therapeutics, Inc. (NASDAQ:STOK) – Equities research analysts at HC Wainwright dropped their FY2029 earnings per share (EPS) estimates for shares of Stoke Therapeutics in a research note issued on Tuesday, August 4th. HC Wainwright analyst A. Ghosh now anticipates that the company will post earnings per share of $1.55 for the year, down from their previous estimate of $1.63. The consensus estimate for Stoke Therapeutics’ current full-year earnings is ($3.22) per share. HC Wainwright also issued estimates for Stoke Therapeutics’ FY2030 earnings at $3.56 EPS.

Other equities analysts have also recently issued reports about the stock. Wedbush boosted their price objective on shares of Stoke Therapeutics from $38.00 to $40.00 and gave the company an “outperform” rating in a research note on Tuesday. The Goldman Sachs Group assumed coverage on shares of Stoke Therapeutics in a research note on Monday, July 13th. They issued a “buy” rating and a $44.00 target price for the company. Guggenheim reaffirmed a “buy” rating and issued a $60.00 target price on shares of Stoke Therapeutics in a report on Tuesday. Chardan Capital reiterated a “buy” rating and set a $35.00 price target on shares of Stoke Therapeutics in a research note on Tuesday. Finally, Weiss Ratings cut shares of Stoke Therapeutics from a “hold (c)” rating to a “sell (d)” rating in a report on Monday, May 11th. Nine equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $43.00.

Stoke Therapeutics Price Performance

Shares of NASDAQ STOK opened at $31.67 on Wednesday. The stock has a fifty day moving average price of $30.40 and a 200 day moving average price of $32.01. Stoke Therapeutics has a 1-year low of $12.72 and a 1-year high of $40.22. The company has a market cap of $1.97 billion, a PE ratio of -11.27 and a beta of 1.20.

Stoke Therapeutics (NASDAQ:STOK) last released its earnings results on Monday, August 3rd. The company reported ($0.93) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.13). Stoke Therapeutics had a negative net margin of 753.60% and a negative return on equity of 59.09%. The company had revenue of $9.32 million during the quarter, compared to analyst estimates of $4.89 million.

Institutional Investors Weigh In On Stoke Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the company. Kestra Advisory Services LLC purchased a new position in Stoke Therapeutics in the 4th quarter valued at approximately $26,000. KBC Group NV purchased a new stake in Stoke Therapeutics during the first quarter worth $36,000. Harbour Investments Inc. boosted its position in Stoke Therapeutics by 312.9% during the fourth quarter. Harbour Investments Inc. now owns 1,185 shares of the company’s stock worth $38,000 after purchasing an additional 898 shares in the last quarter. BNP Paribas Financial Markets grew its holdings in Stoke Therapeutics by 66.2% in the second quarter. BNP Paribas Financial Markets now owns 4,186 shares of the company’s stock valued at $48,000 after purchasing an additional 1,668 shares during the last quarter. Finally, Tower Research Capital LLC TRC grew its holdings in Stoke Therapeutics by 461.0% in the second quarter. Tower Research Capital LLC TRC now owns 4,370 shares of the company’s stock valued at $50,000 after purchasing an additional 3,591 shares during the last quarter.

Insider Activity

In other Stoke Therapeutics news, General Counsel Jonathan Allan sold 1,457 shares of the company’s stock in a transaction dated Tuesday, June 16th. The shares were sold at an average price of $29.95, for a total transaction of $43,637.15. Following the transaction, the general counsel directly owned 18,086 shares in the company, valued at approximately $541,675.70. This represents a 7.46% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Barry Ticho sold 1,795 shares of the stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $30.58, for a total transaction of $54,891.10. Following the completion of the transaction, the insider directly owned 34,826 shares of the company’s stock, valued at approximately $1,064,979.08. This trade represents a 4.90% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 9.60% of the stock is owned by company insiders.

Trending Headlines about Stoke Therapeutics

Here are the key news stories impacting Stoke Therapeutics this week:

• Positive Sentiment: Stoke said it plans to submit a rolling New Drug Application in the first quarter of 2027 for zorevunersen, its potential disease-modifying treatment for Dravet syndrome. Management indicated that its approximately $420 million cash position could support a potential U.S. launch by early 2028, reducing near-term financing concerns. Stoke outlines rolling NDA in Q1 2027
• Positive Sentiment: Second-quarter revenue was approximately $9.3 million, well above the roughly $4.9 million consensus estimate. The company also provided business updates on zorevunersen and its broader RNA medicine pipeline. Stoke Therapeutics second-quarter results
• Positive Sentiment: Guggenheim reaffirmed its “buy” rating and assigned a $60 price target. Wedbush raised its target to $40 from $38 while maintaining an “outperform” rating. Canaccord Genuity reduced its target modestly to $58 from $60 but retained a “buy” rating, and Chardan Capital reiterated its “buy” recommendation. Analyst rating updates
• Neutral Sentiment: Brokerages collectively assigned Stoke an average “moderate buy” recommendation, indicating continued confidence but also some variation in valuation estimates. Brokerage recommendation
• Negative Sentiment: Stoke reported a second-quarter loss of $0.93 per share, wider than the consensus loss estimate of approximately $0.80–$0.82 and compared with a $0.40 loss a year earlier. The result underscores the company’s ongoing cash burn and lack of profitability. Stoke second-quarter earnings

About Stoke Therapeutics

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.